Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation

Cancer Cell(2021)10.1016/j.ccell.2021.10.008Source: DataRank Database

Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation is a research paper published in Cancer Cell (2021). On theSindex it has a DataRank of 0. It has been cited 197 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access197 citations

Free full text

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 10.34)OA: greenTopics (38)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (36)

Riccardo Turrini ORCID,Aspram Minasyan ORCID,David Barras ORCID,Isaac Crespo ORCID,Alizée J Grimm ORCID

Live enrichment

PubMed:34739845 OpenAlex:https://openalex.org/W3208430261

Mats Paulssons Stiftelse

Grant: RO1EB026892

National Institutes of Health

Grant: P50 CA083638

National Institutes of Health

Grant: R01-CA098951

National Institutes of Health

Grant: R01-CA116779

National Institutes of Health

Grant: U54-CA225088

NCI NIH HHS

Grant: R01 CA098951

NCI NIH HHS

Grant: R01 CA116779

NIGMS NIH HHS

Grant: P20 GM130423

NIBIB NIH HHS

Grant: R01 EB026892

NCI NIH HHS

Grant: U54 CA225088

FWCI

10.34

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8861565

publisherhttps://api.elsevier.com/content/article/PII:S1535610821005596?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610821005596?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ccell.2021.10.008

Fields of Study

Immune Cell Function and InteractionCancer Immunotherapy and BiomarkersImmune cells in cancerAntigen-Presenting CellsCD28 AntigensHumansImmune Checkpoint InhibitorsMyeloid CellsNeoplasmsStem Cell Niche

MeSH Terms

Immune Checkpoint InhibitorsAntigen-Presenting CellsHumansNeoplasmsCD28 AntigensMyeloid CellsStem Cell Niche

Keywords

BlockadeCD28Cancer researchCytotoxic T cellImmunologyBiologyT cellCD8AntigenCTLA-4Cell biologyImmune systemReceptorCD40PD-1TILdendritic cellexhaustionmyeloid nicheovariantumor

Sustainable Development Goals

SDG 0: Life in Land

Additional file 1 of Exploring immunotherapy in colorectal cancer

10.6084/m9.figshare.20330034.v1figshare

Additional file 1 of Exploring immunotherapy in colorectal cancer

10.6084/m9.figshare.20330034figshare

Additional file 6 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633568.v1figshare

Additional file 6 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633568figshare

Additional file 7 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633571.v1figshare

Additional file 7 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633571figshare

Additional file 8 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633574.v1figshare

Additional file 8 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633574figshare

Additional file 9 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633577.v1figshare

Additional file 9 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633577figshare

Additional file 10 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633580.v1figshare

Additional file 10 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633580figshare

Additional file 11 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633583.v1figshare

Additional file 11 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633583figshare

Additional file 12 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633586.v1figshare

Additional file 12 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633586figshare

Additional file 13 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633589.v1figshare

Additional file 13 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633589figshare

Additional file 14 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633592.v1figshare

Additional file 14 of CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

10.6084/m9.figshare.26633592figshare